title: Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates.
abstract: We reported an innovative, targeted chemoimmuno drug-delivery system. Although chemoimmunotherapy, as an alternative to or in combination with conventional therapeutic systems, has been in the forefront of recent oncological research, as presently configured, such systems face several major obstacles for efficient clinical application. Here, we establish a novel nano-platform for effective chemoimmunotherapy designed to overcome the drawbacks of conventional cancer therapies, describing a delivery system based on a dendrimer and a single-strand DNA-A9 PSMA (prostate-specific membrane antigen) RNA aptamer hybrid. Employing these vehicles, we demonstrate the promising possibility of this chemoimmuno therapeutic system against prostate cancer in in vivo and in vitro models.
authors.affiliation: Cell Dynamics Research Center, School of Life Sciences, Gwang ju Institute of Science and Technology, Buk-gu, Gwang ju, Republic of Korea.
authors.forename: In-Hyun
authors.initials: IH
authors.lastname: Lee
authors.forename: Sukyung
authors.initials: S
authors.lastname: An
authors.forename: Mi Kyung
authors.initials: MK
authors.lastname: Yu
authors.forename: Ho-Keun
authors.initials: HK
authors.lastname: Kwon
authors.forename: Sin-Hyeog
authors.initials: SH
authors.lastname: Im
authors.forename: Sangyong
authors.initials: S
authors.lastname: Jon
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D000954:Antigens, Surface / Q000096:biosynthesis; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D050091:Dendrimers / Q000737:chemistry*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D004355:Drug Stability; D005434:Flow Cytometry; D043425:Glutamate Carboxypeptidase II / Q000096:biosynthesis; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D018613:Microscopy, Confocal; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D023041:Xenograft Model Antitumor Assays
chemical_list: D000903:Antibiotics, Antineoplastic; D000954:Antigens, Surface; D052157:Aptamers, Nucleotide; D050091:Dendrimers; C104700:PAMAM Starburst; D004317:Doxorubicin; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II